This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

saxagliptin (Onglyza®)

Reference No. 2229

Publication date:

Appraisal information

saxagliptin (Onglyza®) 2.5 mg film-coated tablet
saxagliptin (Onglyza®) 5 mg film-coated tablet

Company: Bristol-Myers Squibb Pharmaceuticals Ltd/AstraZeneca UK Ltd
BNF category: Endocrine system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 06/12/2013

Current Progress

Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, saxagliptin (Onglyza®) cannot be endorsed for use within NHS Wales in adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.
Statement of Advice (SOA)